Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
VIA Pharmaceuticals, Inc. (VIAP)
San Francisco, US
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | 0.00% | +49,900.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -96.86% | -93.33% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%—
-
EPS growth Medical - Pharmaceuticals: +20.2%+55.2% ★ Q4'10: +43.2% (vs Q4'09)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%—
-
EBIT margin Medical - Pharmaceuticals: +6.8%—
-
ROIC Medical - Pharmaceuticals: +6.1%—
-
Share dilution Medical - Pharmaceuticals: +0.0%+2.6% Q4'10: +1.8% (vs Q4'09)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-2.40× Q4'10: -3.99× (vs Q4'09)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2010-11-15 | CRAVES FRED B | Director | P-Purchase | A | Common Stock Warrant | 3,671,806 | 0.07 | 260.7K | 5,205,325 | — | ↗ |
| 2010-04-01 | Wright Karen Steil | Officer | — | D | Common Stock | 0 | 0.00 | — | 63,826 | — | ↗ |
| 2010-03-26 | CRAVES FRED B | Director | P-Purchase | A | Common Stock Warrant | 1,533,519 | 0.17 | 260.7K | 1,533,519 | — | ↗ |
| 2009-03-12 | CRAVES FRED B | Director | P-Purchase | A | Common Stock Warrant | 7,241,618 | 0.12 | 869.0K | 7,241,618 | — | ↗ |
| 2008-12-17 | Taub Rebecca | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 157,500 | — | ↗ |
| 2008-12-17 | Cohen Lawrence Kenneth | Director / Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 419,660 | — | ↗ |
| 2008-12-17 | Bagnall Mark | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.15 | 1.5K | 10,000 | — | ↗ |
| 2008-12-17 | ANDERSON RICHARD L | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.15 | 1.5K | 10,000 | — | ↗ |
| 2008-12-05 | Taub Rebecca | Officer | P-Purchase | A | Common Stock | 32,500 | 0.30 | 9.8K | 32,500 | — | ↗ |
| 2008-01-15 | Taub Rebecca | Officer | A-Award | A | Stock Option (right to buy) | 235,000 | 2.90 | 681.5K | 235,000 | — | ↗ |
| 2008-01-14 | Taub Rebecca | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-12-17 | OLUKOTUN ADEOYE Y | Officer | A-Award | A | Stock Option (right to buy) | 120,000 | 2.38 | 285.6K | 120,000 | — | ↗ |
| 2007-12-17 | Cohen Lawrence Kenneth | Director / Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 2.38 | 1.43M | 600,000 | — | ↗ |
| 2007-12-17 | Bagnall Mark | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.38 | 47.6K | 20,000 | — | ↗ |
| 2007-12-17 | ANDERSON RICHARD L | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.38 | 47.6K | 20,000 | — | ↗ |
| 2007-11-06 | Flynn James E | 10% Owner | S-Sale | D | Common Stock | 39,904 | 3.21 | 128.1K | 1,244,708 | — | ↗ |
| 2007-11-05 | Flynn James E | 10% Owner | S-Sale | D | Common Stock | 64 | 3.38 | 216.00 | 1,284,612 | — | ↗ |
| 2007-10-31 | Flynn James E | 10% Owner | S-Sale | D | Common Stock | 74 | 3.97 | 293.41 | 1,284,676 | — | ↗ |
| 2007-10-26 | Flynn James E | 10% Owner | S-Sale | D | Common Stock | 1,459 | 3.92 | 5.7K | 1,284,750 | — | ↗ |
| 2007-10-25 | Flynn James E | 10% Owner | S-Sale | D | Common Stock | 1,359 | 3.88 | 5.3K | 1,286,209 | — | ↗ |
| 2007-10-24 | Flynn James E | 10% Owner | S-Sale | D | Common Stock | 8,322 | 3.91 | 32.6K | 1,287,568 | — | ↗ |
| 2007-10-23 | Flynn James E | 10% Owner | S-Sale | D | Common Stock | 64 | 3.97 | 253.76 | 1,295,890 | — | ↗ |
| 2007-10-22 | Flynn James E | 10% Owner | S-Sale | D | Common Stock | 259 | 3.98 | 1.0K | 754,610 | — | ↗ |
| 2007-10-18 | Flynn James E | 10% Owner | S-Sale | D | Common Stock | 582 | 3.98 | 2.3K | 1,296,399 | — | ↗ |
| 2007-10-17 | Flynn James E | 10% Owner | S-Sale | D | Common Stock | 1,995 | 4.03 | 8.0K | 755,207 | — | ↗ |
| 2007-08-08 | ANDERSON RICHARD L | Director | P-Purchase | A | Common Stock | 10,000 | 2.43 | 24.3K | 10,000 | — | ↗ |
| 2007-08-02 | OLUKOTUN ADEOYE Y | Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 3.48 | 139.2K | 95,758 | — | ↗ |
| 2007-08-02 | Cohen Lawrence Kenneth | Director / Officer | A-Award | A | Stock Option (right to buy) | 185,000 | 3.48 | 643.8K | 296,516 | — | ↗ |
| 2007-06-29 | Flynn James E | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 757,202 | — | ↗ |
| 2007-06-05 | OLUKOTUN ADEOYE Y | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-06-05 | Cohen Lawrence Kenneth | Director / Officer | A-Award | A | Common Stock | 119,660 | 0.00 | — | 119,660 | — | ↗ |
| 2007-06-05 | CRAVES FRED B | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-06-05 | Bagnall Mark | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-06-05 | ANDERSON RICHARD L | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas Quertermous FACC | Chief Scientific Officer & Member of Scientific Advisory Board | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VIAP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
